This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (4)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal

Arch Ophthalmol. 1998;116:1512-1513.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

IN THIS issue of the ARCHIVES, Green¹ elegantly reviews clinical issues about the potential use of marijuana and cannabinoids in glaucoma therapy. This editorial deals briefly with the scientific foundation underlying the marijuana-glaucoma controversy, and like the review, concludes that data, not demagoguery, should guide our path.

Glaucoma results in the degeneration of retinal ganglion cells and their optic nerve axons that carry visual impulses from the eye to the brain. Marijuana and cannabinoids affect the major risk factor for glaucoma, elevation of intraocular pressure (IOP), which is regulated by the hydrodynamic systems at the front of the eye.

The ciliary body secretes aqueous humor, which flows into the anterior chamber, nourishes the lens and the cornea, and leaves the eye via 2 routes. One route is through the trabecular meshwork, a lattice of connective tissue and endothelial cells embedded in a glycosaminoglycan-like ground substance, then into the Schlemm canal . . . [Full Text of this Article]

RELATED ARTICLE

Marijuana Smoking vs Cannabinoids for Glaucoma Therapy
Keith Green
Arch Ophthalmol. 1998;116(11):1433-1437.
ABSTRACT | FULL TEXT